{"id":"https://openalex.org/W2024196844","doi":"https://doi.org/10.1182/blood-2006-07-035725","title":"A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome","display_name":"A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome","publication_year":2007,"publication_date":"2007-01-30","ids":{"openalex":"https://openalex.org/W2024196844","doi":"https://doi.org/10.1182/blood-2006-07-035725","mag":"2024196844","pmid":"https://pubmed.ncbi.nlm.nih.gov/17264294"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2006-07-035725","doi":"https://doi.org/10.1182/blood-2006-07-035725","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2006-07-035725","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014838075","display_name":"Pierre Fenaux","orcid":"https://orcid.org/0000-0002-0468-3553","observed_orcids":["https://orcid.org/0000-0002-0468-3553"]},"institutions":[{"id":"https://openalex.org/I4210129146","display_name":"H\u00f4pital Avicenne","ror":"https://ror.org/03n6vs369","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210129146"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Pierre Fenaux","raw_affiliation_strings":["Ho\u0302pital Avicenne, Paris, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ho\u0302pital Avicenne, Paris, France;","institution_ids":["https://openalex.org/I4210129146"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087963156","display_name":"Azra Raza","orcid":"https://orcid.org/0000-0002-9734-5210","observed_orcids":["https://orcid.org/0000-0002-9734-5210"]},"institutions":[{"id":"https://openalex.org/I1285301757","display_name":"Rush University Medical Center","ror":"https://ror.org/01j7c0b24","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1285301757"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Azra Raza","raw_affiliation_strings":["Rush Cancer Institute, Chicago, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rush Cancer Institute, Chicago, IL;","institution_ids":["https://openalex.org/I1285301757"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112225731","display_name":"Ghulam Jeelani Mufti","orcid":"https://orcid.org/0009-0004-7335-9230","observed_orcids":["https://orcid.org/0009-0004-7335-9230"]},"institutions":[{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ghulam J. Mufti","raw_affiliation_strings":["Kings College, London, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kings College, London, United Kingdom;","institution_ids":["https://openalex.org/I183935753"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090793417","display_name":"Carlo Aul","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carlo Aul","raw_affiliation_strings":["St Johannes Hospital, Duisburg, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St Johannes Hospital, Duisburg, Germany;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113559069","display_name":"Ulrich Germing","orcid":"https://orcid.org/0009-0005-6027-6388","observed_orcids":["https://orcid.org/0009-0005-6027-6388"]},"institutions":[{"id":"https://openalex.org/I44260953","display_name":"Heinrich Heine University D\u00fcsseldorf","ror":"https://ror.org/024z2rq82","country_code":"DE","type":"education","lineage":["https://openalex.org/I44260953"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Ulrich Germing","raw_affiliation_strings":["Heinrich Heine University, Du\u0308sseldorf, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Heinrich Heine University, Du\u0308sseldorf, Germany;","institution_ids":["https://openalex.org/I44260953"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090435894","display_name":"Hagop M. Kantarjian","orcid":"https://orcid.org/0000-0002-1908-3307","observed_orcids":["https://orcid.org/0000-0002-1908-3307"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hagop Kantarjian","raw_affiliation_strings":["University of Texas, M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas, M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016061346","display_name":"Larry Dean Cripe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039234","display_name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center","ror":"https://ror.org/00g1d7b60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039234","https://openalex.org/I592451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Larry Cripe","raw_affiliation_strings":["Indiana University Cancer Center, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indiana University Cancer Center, Indianapolis, IN","institution_ids":["https://openalex.org/I4390039234"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091176390","display_name":"Ren\u00e9 Kerstens","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rene\u0301 Kerstens","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061992932","display_name":"Peter De Porre","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter De Porre","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["University of Texas, M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas, M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":11.2932,"has_fulltext":false,"cited_by_count":104,"citation_normalized_percentile":{"value":0.98633566,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"109","issue":"10","first_page":"4158","last_page":"4163"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tipifarnib","display_name":"tipifarnib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/farnesyltransferase-inhibitors","display_name":"farnesyltransferase inhibitors","score":0.9409999847412109},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9959999918937683},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.8579999804496765},{"id":"https://openalex.org/keywords/hematological-response","display_name":"hematologic response","score":0.7400000095367432},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9240000247955322},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9769999980926514},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.9819999933242798},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7730000019073486}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8249613046646118},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.7294723391532898},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6755913496017456},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5833039283752441},{"id":"https://openalex.org/C2777827897","wikidata":"https://www.wikidata.org/wiki/Q5436005","display_name":"Farnesyltransferase inhibitor","level":5,"score":0.5805710554122925},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.5113136768341064},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4586901366710663},{"id":"https://openalex.org/C2780240888","wikidata":"https://www.wikidata.org/wiki/Q6052586","display_name":"International Prognostic Scoring System","level":4,"score":0.4386231601238251},{"id":"https://openalex.org/C2778396349","wikidata":"https://www.wikidata.org/wiki/Q410994","display_name":"Farnesyltransferase","level":4,"score":0.4295831322669983},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4226980209350586},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3411597013473511},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.1865079700946808},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.0},{"id":"https://openalex.org/C57790582","wikidata":"https://www.wikidata.org/wiki/Q901141","display_name":"Prenylation","level":3,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001803","descriptor_name":"Blood Transfusion","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009190","descriptor_name":"Myelodysplastic Syndromes","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009190","descriptor_name":"Myelodysplastic Syndromes","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D009190","descriptor_name":"Myelodysplastic Syndromes","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D012306","descriptor_name":"Risk","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051231","descriptor_name":"Farnesyltranstransferase","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1182/blood-2006-07-035725","doi":"https://doi.org/10.1182/blood-2006-07-035725","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2006-07-035725","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},{"id":"pmid:17264294","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17264294","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"Clinical Trial, Phase II"},{"id":"pmh:oai:kclpure.kcl.ac.uk:publications/ab668dbb-fef2-4494-b493-d60e3fcae508","doi":null,"is_oa":false,"landing_page_url":"https://kclpure.kcl.ac.uk/portal/en/publications/ab668dbb-fef2-4494-b493-d60e3fcae508","pdf_url":null,"source":{"id":"https://openalex.org/S4306400216","display_name":"Research Portal (King's College London)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I183935753","host_organization_name":"King's College London","host_organization_lineage":["https://openalex.org/I183935753"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Fenaux, P, Raza, A, Mufti, G J, Aul, C, Germing, U, Kanterjian, H, Cripe, L, Kerstens, R, De Porre, P & Kurzrock, R 2007, 'A multicenter phase 2 study of the famesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome', Blood, vol. 109, no. 10, pp. 4158 - 4163. https://doi.org/10.1182/blood-2006-07-035725","raw_type":"info:eu-repo/semantics/publishedVersion"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":30,"referenced_works":["https://openalex.org/W187238933","https://openalex.org/W194463696","https://openalex.org/W1501742295","https://openalex.org/W1541537086","https://openalex.org/W1558058709","https://openalex.org/W1997091454","https://openalex.org/W1998688881","https://openalex.org/W2002226188","https://openalex.org/W2028516182","https://openalex.org/W2065484973","https://openalex.org/W2071831134","https://openalex.org/W2079472461","https://openalex.org/W2081279521","https://openalex.org/W2085339409","https://openalex.org/W2096358100","https://openalex.org/W2102901804","https://openalex.org/W2106584820","https://openalex.org/W2129510594","https://openalex.org/W2131872320","https://openalex.org/W2143568970","https://openalex.org/W2146472745","https://openalex.org/W2155167738","https://openalex.org/W2167734044","https://openalex.org/W2172104048","https://openalex.org/W2567004787","https://openalex.org/W2569690486","https://openalex.org/W2588102314","https://openalex.org/W3135020720","https://openalex.org/W4239576136","https://openalex.org/W4250402886"],"related_works":["https://openalex.org/W7099621824","https://openalex.org/W2553924023","https://openalex.org/W2136099575","https://openalex.org/W2077777928","https://openalex.org/W2591215796","https://openalex.org/W2045528227","https://openalex.org/W2043901516","https://openalex.org/W2041091333","https://openalex.org/W2979652590","https://openalex.org/W2115868832"],"abstract_inverted_index":{"This":[0],"multicenter":[1],"phase":[2],"2":[3],"study":[4],"evaluated":[5],"the":[6,32,69,72,82,123,153],"use":[7],"of":[8,36,100,155],"tipifarnib":[9,25],"(R115777)":[10],"in":[11],"patients":[12,41,57,156],"with":[13,157],"poor-risk":[14],"myelodysplastic":[15],"syndrome":[16],"(MDS;":[17],"French-American-British":[18],"classification).":[19],"Patients":[20],"(n":[21],"=":[22],"82)":[23],"received":[24],"300":[26],"mg":[27],"orally":[28],"twice":[29],"daily":[30],"for":[31,152],"first":[33],"21":[34],"days":[35],"each":[37],"28-day":[38],"cycle.":[39],"Twenty-six":[40],"(32%)":[42,121],"responded":[43],"to":[44,85,159],"tipifarnib:":[45],"12":[46,70],"(15%)":[47],"complete":[48],"responses":[49,140],"(CRs)":[50],"and":[51,93,119,141],"14":[52],"(17%)":[53],"hematologic":[54],"improvements;":[55],"37":[56],"(45%)":[58],"had":[59],"stable":[60],"disease":[61],"(modified":[62],"International":[63],"Working":[64],"Group":[65],"criteria,":[66],"2006).":[67],"Among":[68],"CRs,":[71],"median":[73,83],"response":[74],"duration":[75],"was":[76,87,109],"11.5":[77],"months":[78,89,111],"(range,":[79,90],"2.0-21.9":[80],"months),":[81,92],"time":[84,99],"progression":[86],"12.4":[88],"3.9-23.8":[91],"7":[94],"were":[95,122,133,145],"still":[96],"alive":[97],"at":[98],"analysis":[101],"(all":[102],">":[103],"3":[104],"years).":[105],"Median":[106],"overall":[107],"survival":[108],"11.7":[110],"(95%":[112],"CI,":[113],"9.4-15.0).":[114],"Grade":[115],"3-4":[116],"neutropenia":[117],"(18%)":[118],"thrombocytopenia":[120],"most":[124],"common":[125],"treatment-related":[126],"adverse":[127,131],"events;":[128],"severe":[129],"nonhematologic":[130],"events":[132],"rarely":[134],"reported.":[135],"In":[136],"this":[137],"study,":[138],"durable":[139],"acceptable":[142],"side":[143],"effects":[144],"observed.":[146],"Tipifarnib":[147],"is":[148],"an":[149],"active":[150],"agent":[151],"treatment":[154],"intermediate-":[158],"high-risk":[160],"MDS.":[161]},"counts_by_year":[{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":12},{"year":2012,"cited_by_count":8}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}